ER THIS AM
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
Positive
Strong cash position of $264 million with runway extended into 2027
Significant revenue increase to $34.1 million, up from $7.2 million YoY
Net loss improved to $42.7 million from $59.3 million YoY
Secured $47 million in payments from AstraZeneca partnership
Positive
Strong cash position of $264 million with runway extended into 2027
Significant revenue increase to $34.1 million, up from $7.2 million YoY
Net loss improved to $42.7 million from $59.3 million YoY
Secured $47 million in payments from AstraZeneca partnership
Negative
R&D expenses increased to $69.7 million from $62.7 million YoY
SG&A expenses rose to $14.2 million from $12.1 million YoY
Deprioritization of UCAR
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2882Followers
108Following
30KVisitors
Follow